2020/05/23

thumbnail

China's COVID-19 vaccine trial shows promising results


      ,

221

A potential coronavirus vaccine developed in China appeared safe and able to generate an immune response after an early trial in more than 100 people, according to a new study.

1081860

28

114T

In the new study, published Friday (May 22) in the journal The Lancet, the researchers tested Ad5-nCoV in 108 healthy people ages 18 to 60 who didn't have COVID-19. Participants received either a low, middle or high dose of the vaccine.

In the new study, published Friday (May 22) in the journal The Lancet, the researchers tested Ad5-nCoV in 108 healthy people ages 18 to 60 who didn't have COVID-19. Participants received either a low, middle or high dose of the vaccine.

Two weeks after vaccination, participants in all three groups showed some level of an immune response to the virus. By 28 days, nearly all participants had developed antibodies that bound to SARS-CoV-2 (but don't necessarily attack the virus), and about half of the participants in the low- and middle- dose groups and three-quarters of participants in the high-dose group developed "neutralizing antibodies," which bind to and disable the virus to prevent it from infecting cells.


However, Chen Wei also pointed out that the relevant results must be treated with caution. The development of vaccines will face unprecedented challenges, and the ability to elicit an immune response does not necessarily mean that the vaccine can protect people from new coronavirus infection. We still have a long way to go before this vaccine can be used by everyone. "

Richard Horton, editor-in-chief of The Lancet magazine, shared this progress via social media, saying that the first human trial of COVID-19 vaccine finds that it is safe, well tolerated, and can induce a rapid immunity response. "These results represent an important milestone."

100

     

 |

    |


Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

Blogroll